SUMAIRA AHMED: Open Payments
NPI 1043247687 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,494 in 65 payments from 12 companies in 2025. Trend: 2023 $1,025 · 2024 $1,593 · 2025 $1,494
Food & beverage: $1,494
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $286 |
| Axsome Therapeutics, Inc. | 7 | $281 |
| ABBVIE INC. | 14 | $255 |
| Otsuka America Pharmaceutical, Inc. | 11 | $163 |
| Janssen Pharmaceuticals, Inc | 4 | $121 |
| Lundbeck LLC | 5 | $111 |
| Neurocrine BioSciences, Inc. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Alkermes, Inc. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
Products named: CAPLYTA, Auvelity, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, INVEGA SUSTENNA, INGREZZA, UZEDY.
Industry payments across TX — which companies pay providers there.
